---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016862"
form_type: "8-K"
ticker: "SGHT"
cik: "0001531177"
company_name: "Sight Sciences, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:48:06.517247+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sight Sciences Q2 revenue $17.2M (+37% YoY); net loss $23.8M; FY22 guidance $68-72M

## Summary
- Surgical Glaucoma revenue $15.9M (+33% YoY); Dry Eye revenue $1.3M (+143% YoY).
- Gross margin expanded to 84% from 82% YoY on manufacturing cost reductions.
- Operating expenses rose 75% to $37.4M, driven by personnel and R&D investment.
- Cash and equivalents $220.1M; total debt $33.0M as of June 30, 2022.
- Full-year 2022 revenue guidance: $68-72M, representing 39-47% growth over 2021.

## SEC filing metadata
- accession: 0000950170-22-016862
- form_type: 8-K
- ticker: SGHT
- cik: 0001531177
- company_name: Sight Sciences, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1531177/000095017022016862/0000950170-22-016862-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1531177/000095017022016862/sght-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016862
- JSON: https://secwatch.observer/filing/0000950170-22-016862.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016862.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.